9 Meters Biopharma Inc. (NASDAQ: NMTR) stock experienced fluctuations on June 14, 2024. The stock opened at $0.46 and reached a high of $0.485 before falling to a low of $0.42. It closed at $0.43, representing a decrease of 1.15% for the day. Trading volume for the day was 1,043,022 shares [1].
How have 9 Meters Biopharma shares performed recently?
In the past month, 9 Meters Biopharma's stock has seen significant volatility. As of June 14, 2024, the stock was trading around $0.43 per share. Over the last year, the stock has experienced a substantial decline, with its price significantly lower than a year ago [2].
What is the outlook for 9 Meters Biopharma?
The company is focused on developing and commercializing therapeutics in areas such as oncology and immunology. Recent news has often centered on its clinical trial progress and potential regulatory milestones. Analysts' ratings and price targets can offer insights into the projected future performance of NMTR stock [3].
What are the main drugs 9 Meters Biopharma is developing?
9 Meters Biopharma's pipeline includes drug candidates targeting various diseases. Information regarding their most advanced programs, such as those in oncology, can be found in company reports and scientific publications. These efforts aim to address unmet medical needs [4].
When does 9 Meters Biopharma's key drug patent expire?
Patent exclusivity for 9 Meters Biopharma's drug candidates is crucial for its long-term commercial success. DrugPatentWatch.com tracks patent expiry dates for pharmaceutical products, which is a key factor in the competitive landscape, influencing the potential entry of generic or biosimilar competition [5]. Information specific to NMTR's pipeline patents would be available on such specialized databases.
Who are 9 Meters Biopharma's main competitors?
The biopharmaceutical industry is highly competitive. 9 Meters Biopharma faces competition from other companies developing treatments for oncology and immunology. These competitors may have established products or similar pipeline candidates [4].
What do financial analysts say about 9 Meters Biopharma stock?
Financial analysts provide ratings and price targets for 9 Meters Biopharma stock, which can influence investor sentiment. These assessments are often based on the company's clinical trial data, pipeline, financial health, and market trends [3].
Sources:
[1] https://finance.yahoo.com/quote/NMTR/history
[2] https://finance.yahoo.com/quote/NMTR/
[3] https://finance.yahoo.com/quote/NMTR/analysis
[4] https://www.9metersbio.com/
[5] https://drugpatentwatch.com/